1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
ENCell Co., Ltd.

ENCell Co., Ltd.

KKRX:456070
4,825.00
KRW
-75.00
(-1.53%)
-1,791.51EPS
84.60BMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7,618.64
20,796.58
1,543.74
1,703.8
819.53
483.83
380.24
Basic EPS, GAAP
-36,336.04
-35,003.91
-9,548
-818
-1,729
-1,482
-1,791.51
Free Cash Flow per Basic Share
-9,564.25
-66,203.71
-2,371.6
-1,356.77
-1,220.86
-1,227.86
-1,217.33
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-254.78
-388.99
-2,552.18
4,007.37
4,474.03
3,581.66
2,532.09
Tangible Book Value per Share
-257.56
-400.85
-2,565.36
3,976.21
4,449.44
3,561.82
2,514.66
Basic Weighted Avg Shares
- -
- -
5
6
9
11
11
Sales/Revenue/Turnover
1,404
3,909
7,367
10,526
7,209
5,259
4,164
Operating Margin (%)
-159.99
-64.55
-126.44
-111.68
-217.54
-339.26
-435.75
Depreciation Expense
199
890
2,964
4,239
4,498
4,705
4,719
Net Income, GAAP
-6,697
-6,579
-45,567
-5,054
-15,210
-16,108
-19,620
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-476.94
-168.32
-618.5
-48.01
-210.97
-306.3
-471.16
Working Capital
-4,404
-19,481
-42,786
20,186
32,856
40,485
30,179
LT Debt
5,231
1,980
3,978
3,097
3,750
11,735
12,098
Total Equity
-2,382
-3,633
-23,836
38,016
48,168
39,404
27,857
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-35.52
-36.79
-57.72

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,280
1,011
1,040
LT Borrowings
9,003
9,243
9,766
LT Finance Leases
2,733
2,392
2,332
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
200,008
162,162
84,602

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
43,702
40,006
35,160
Cash, Cash Equivalents & STI
38,510
34,436
31,398
Accounts Receivable, Net
1,224
691
715
Inventories
1,123
1,630
1,929
Total Current Liabilities
3,217
4,412
4,980
Payables & Accruals
- -
- -
- -
ST Debt
1,280
1,011
1,040
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
71.52%
-18.2%
Free Cash Flow
- -
124.66%
24.26%
Net Income, GAAP
- -
141.77%
5.9%
Sales/Revenue/Turnover
- -
50.23%
-27.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,790
1,859
1,469
2,092
7,209
2025
1,094
1,178
1,546
1,442
5,259
2026
309
868
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-277.96
-394
-453
-482.55
-1,729
2025
-431.44
-398
-330.48
-323.03
-1,482
2026
-479.66
-656
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jong-Wook Chang
Full Time Employees
112
Sector
Health technology
Industry
Biotechnology
Address
701, Youngdong Daero Seoul SL South Korea
IPO Date
Aug 23, 2024
Website
encellinc.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
ENCell Co. Ltd. ENCell Co., Ltd. (456070.KQ) develops and manufactures cell and gene-based biopharmaceutical products primarily focused on advanced therapies for rare and intractable diseases. The company offers contract development and manufacturing organization (CDMO) services through its ROCKET Platform, which supports multi-product GMP production for cell therapies including stem cells, CAR-T, NK cells, and exosomes, as well as gene therapies utilizing lentivirus and AAV vectors; contract quality testing (CQT) services covering raw materials, in-process controls (IPC), drug substances (DS), drug products (DP), and stability testing; and an in-house pipeline featuring EN001 (also referred to as EN00), an allogeneic Wharton's jelly-derived mesenchymal stem cell therapy targeting Charcot-Marie-Tooth disease, alongside programs for Duchenne muscular dystrophy, cancer immunotherapy, and AAV-based gene therapies. ENCell Co. Ltd. (456070.KQ) operates three PIC/S-compliant GMP facilities in South Korea, providing end-to-end solutions from research and process development to quality assurance and commercialization support for global clients in the biotechnology sector, with a target market encompassing pharmaceutical companies, research institutions, and developers of regenerative medicines. Founded in March 2018 as a spin-off from Samsung Medical Center and headquartered at WE Tower in Cheongdam-dong, Seoul, South Korea, the company leverages proprietary platform technologies like ENCT to address challenges in cell senescence, efficacy, and high-yield production. Recent developments include selection for the 2020 Seoul Business Agency Bio-Medical Technology Commercialization Support Program to advance its Duchenne muscular dystrophy treatment in collaboration with Samsung Medical Center; a strategic alliance and licensing agreement with Lucy Biotech for the EN001 mesenchymal stem cell therapy; clinical trial approval for EN001 by the Ministry of Food and Drug Safety in May 2021 following preclinical validation of nerve sheath regeneration, muscle regeneration, and safety; and ongoing expansion of GMP capabilities to secure international contracts.